Cell Therapy Technologies Market worth .8 Billion | MarketsandMarkets from Priya's blog

Cell Therapy Technologies Market in terms of revenue was estimated to be worth $4.2 Billion in 2023 and is poised to reach $7.8 Billion by 2028, growing at a CAGR of 13.3% from 2023 to 2028 according to a new report by MarketsandMarkets™. Major factors driving the market growth at significant CAGR are increasing the prevalence of chronic diseases, increasing the funding for research, and the launch of novel products in the market by key market players.

Download an Illustrative overview: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=213334978

The cell processing segment accounted for the largest share of the process segment in the cell therapy technologies market in 2022.

Based on process, the global cell therapy technologies market is segmented into cell processing, cell preservation, distribution & handling, process monitoring & quality control. In 2022, the cell processing segment held dominant share in cell therapy technologies market. The factors attributable to the dominance are adoption of technologically advance products and instruments in the market.

The biopharmaceutical & biotechnology companies sub segment accounted for the largest share of the end user segment in the cell therapy technologies market in 2022.

Based on end users, the cell therapy technologies market is segmented into biopharmaceutical & biotechnology companies, CROS & CMOs, research institutes & cell banks. In 2022, the biopharmaceutical & biotechnology companies segment accounted for the largest share of the cell therapy technologies market. The segment held the dominant share in the market owing to various factors such as increased funding, rising academia and biopharma collaboration for research and development in cell-therapy products.

North America dominated the cell therapy technologies market.

Based on region, the cell therapy technologies market is segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. In 2022, North America dominated the market, followed by Europe. The increasing funding for research for chronic diseases and the presence of top players operating in the region are key factors supporting the growth of the North America cell therapy technologies market. The Asia Pacific market is projected to grow at the highest CAGR during the forecast period. Increased adoption of cell-based therapy in emerging countries coupled with emphasis on geographical expansions by key market players in emerging countries these are some of the factors anticipated to contribute to the cell therapy technologies market growth in the Asia Pacific.

Request Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=213334978

Cell Therapy Technologies Market Dynamics:

Drivers:

1. Rising incidence of chronic and infectious diseases

Restraints:

1. High cost of cell-based research and low success rate

Opportunities:

1. Increased focus on personalized medicine

Challenges:

1. Survival of small players and new entrants

Key Market Players:

The cell therapy technologies market is consolidated, with a small number of players competing for market shares. Thermo Fisher Scientific Inc. (US), Merck KGaA (Germany), Lonza Group (Switzerland)Danaher Corporation (US), Sartorius AG (Germany) are some of the leading players in this market. Most companies in the market focus on organic and inorganic growth strategies, such as product launches, expansions, acquisitions, partnerships, agreements, and collaborations, to increase their product offerings, cater to the unmet needs of customers, increase their profitability, and expand their presence in the global market.

Recent Developments:

• In March 2023, Thermo fisher scientific Inc. entered into collaboration with Arsenal biosciences Inc. The collaboration allows development of manufacturing process for new cancer treatments. This research and process development-focused collaboration has enabled ArsenalBio to develop a robust manufacturing process for their next-generation, programmable autologous T cells for the treatment of cancer.
• In March 2023, Danaher entered into partnership with the University of pennsylvania's center for cellular immunotherapies to solve manufacturing difficulties that are affecting the adoption of cell therapies.
• In March 2023, Lonza and Vertex have entered a strategic collaboration to facilitate the manufacturing of Vertex's portfolio of investigational stem cell-derived islet cell therapies. As part of the collaboration, Vertex and Lonza will establish a dedicated manufacturing facility specifically for T1D cell therapies.

Get 10% Free Customization on this Report: https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=213334978